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Treating morning sickness in the United States—changes
in prescribing are needed
Gideon Koren, MD, FRCPC, FACMT, FAACTPresently, 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy
in the United States are with medications not labeled for use in pregnancy, not indicated
for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the
Food and Drug Administration. The use of ondansetron for nausea and vomiting in
pregnancy has increased from 50,000 monthly prescriptions in 2008 to 110,000 at the
end of 2013, despite unresolved issues regarding fetal safety and Food and Drug
Administration warnings about serious dysrhythmias. In April 2013, the Food and Drug
Administration approved the combination of doxylamine and pyridoxine, specifically for
nausea and vomiting in pregnancy symptoms. Now that a safe and effective drug is
available in the United States, there is no reason for women to be exposed to a drug of
unproven maternal and fetal safety.
Key words: nausea and vomiting, ondansetron, pregnancyausea and vomiting of pregnancyN (NVP) is the most common med-
ical condition in pregnancy, affecting an
estimated 80% of pregnant women.1
Because the withdrawal of Bendectin
(delayed release doxylamine 10 mg-
pyridoxine 10 mg; WMS Merrell Dow,
Cincinnati, OH) from the US market in
1983, American women did not have ac-
cess to a Food and Drug Administration
(FDA)-approved drug for NVP for
30 years, until the same drug combina-
tion (under the trade name Diclegis;
Duchesnay Inc., Blainville, Canada) was
approved by the FDA in April 2013.2
The withdrawal of Bendectin from the
US left American women without an
FDA-approved drug for NVP and was
associated with a 3-fold increased riskFrom The Motherisk Program, The Hospital for
Sick Children and University of Toronto,
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severe forms of this condition.3
Presently, 97.7% of prescriptions for the
treatment of NVP in the US are with
medications not labeled for use in preg-
nancy, not indicated for NVP, and not
classiﬁed as safe in pregnancy (FDA cate-
gory A). The use of ondansetron for the
treatment of NVP has steadily increased
from 50,000 prescriptions per month in
2008 to110,000 at the endof 2013 (Figure).
This means that around 1 million
pregnant American women are exposed
to ondansetron out of 4 million pregnan-
cies a year.Ondansetron (GlaxoSmithKlein
Inc, Philadelphia, PA) is a serotonin
5-HT3 receptor antagonist, originally
introduced to prevent nausea and vom-
iting induced by cancer chemotherapy,
radiation therapy, and surgery. The fact
that ondansetron became generic in
2007, and hence its price dropped, might
have been an important cause for this
increase, with easier access to Medicaid
and health maintenance organizations.
Prescribing ondansetron as a ﬁrst line op-
tion is not consistent with American
Professors in Gynecology and Obstetrics
andAmericanCollegeofObstetricians and
Gynecologists evidence-based recommen-
dations for the management of NVP.4,5
It should be remembered that most
drugs used in pregnancy, including steroidsDECEMBER 2014for the prevention of respiratory distress
syndrome, all tocolytic agents, and mag-
nesium sulfate for the prevention of cere-
bral palsy, to mention a few, have not been
approvedby theFDA.Yet, they are standard
of care. In contrast, in the case of ondan-
setron there are unresolved issues sur-
rounding the fetal and maternal safety,
including recent warnings by the FDA on
itspotential to cause seriousdysrhythmias.6
Fetal safety concerns regarding
ondansteron
The fetal safety of the ondansetron was
ﬁrst investigated in humans by Einarson
et al7 in 2004 through a prospective
controlled cohort study of 176 women,
in whom we could not detect an
increased teratogenic risk. However,
this sample size had the statistical
power to rule out only a 5-fold increased
risk of major malformations, and not
any speciﬁc malformation. In February
2013, Pasternak et al8 reported that
ondansetron was not associated with
increased malformation rates when used
for morning sickness. This was based
on retrospective analysis of data from
the Danish Birth Registry, collected be-
tween 2004 and 2011 and linked to the
National Prescription Register. Each of
the 1970 women exposed to ondanse-
tron was matched to 4 unexposed con-
trols. Of note, the mean age at exposure
was 10 gestational weeks, which means
that half of the cases were exposed to
ondansetron at later than 10 gestational
weeks, when the morphologic malfor-
mations sought in this study could not
be produced any more. This can cause a
bias toward the null, diluting an existing
risk because of inclusion of cases that
were not exposed during embryogenesis.
However, in August of 2013, Andersen
et al9 from Denmark presented a second
study using the same Danish registries
covering more years (1997-2010) and
more pregnant women (897,018 vs
FIGURE
Sales of antiemetics for NVP in the US, 2008-2014
IMS National Prescription Audit from 2008 to 2014.
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Andersen’s study detected a 2-fold
increased risk of cardiac malformations
with ondansetron (odds ratio [OR], 2.0;
95% conﬁdence interval [CI], 1.3e3.1),
leading to an overall 30% increased risk
of major congenital malformations. To
rule out confounding by indication,
Andersen et al9 also examined metoclo-
pramide taken for morning sickness,
detecting no increase in teratogenic risk.
The fact that the same large registry can
be investigated to yield such opposing re-
sults is concerning.There is an exponential
rise in use of prescription database linkage
to birth registries. None of these were
designed speciﬁcally to address fetal drug
safety, and theremaybeﬂaws in thequality
and completeness of the available data.
Of potential importance, a recent large
case control study by the Sloan epidemi-
ology unit and the Centers of Disease
Control and Prevention, has reported a
2-fold increased risk for cleft palate
associated with ondansetron taken for
NVP in the ﬁrst trimester of pregnancy
(OR, 2.37; 95% CI, 1.28e4.76).10
Maternal safety concerns regarding
ondansetron
The maternal safety of ondansetron has
been challenged in June 2012, when the
FDA issued a warning of possible serious
cardiac output (QT) prolongation and
Torsade the Pointe among people receiving
ondansetron.11 As a result, the FDA re-
quires strict workup of patients receiving
ondansetron, to rule out long QT, elec-
trolyte imbalance, congestive heart failure
or taking concomitant medications that
prolong the QT interval.12 Because this
drug is not approved by the FDA for
pregnant women, the FDA did not spe-
ciﬁcally address precautions in pregnancy.
However, in the context of NVP, women
with severe NVP often exhibit electrolyte
abnormalities (hypokalenia or hypomag-
nesemia). Presently, counseling ofwomen
who receive ondansetron for morning
sickness suggests that these FDA pre-
cautions are not being followed.
Serotonin syndrome is a life-
threatening disorder of excessive seroto-
nergic activity, typically occurring when
2 or more serotonin-modifying agents
are used simultaneously, although it mayalso occur with a single agent.12 From
Jan. 1, 1998, to Dec. 30, 2002, Health
Canada received 53 reports of suspected
serotonin syndrome,most often reported
with the use of selective serotonin re-
uptake inhibitors (SSRIs), monoamine
oxidase inhibitors and selective serotonin-
norepinephrine reuptake inhibitors.
The clinical presentation of sere-
tonergic syndrome is characterized by
the triad of cognitive or behavioral
changes (confusion, agitation, lethargy,
coma), autonomic instability (hyper-
thermia, tachycardia, diaphoresis, nausea
and vomiting, diarrhea and dilated
pupils) and neuromuscular changes
(myoclonus, hyperreﬂexia and tremor).12
Critically, serotonin syndrome has also
been reportedwith the concomitant use of
5-HT3 receptor antagonists (eg, ondanse-
tron, dolasetron, granisetron).13 Because
large numbers of pregnant women
suffering from depression are prescribed
SSRIs, and up to 80% experiencemorning
sickness a possible interaction between
SSRIs and ondansetron, leading to sero-
tonin syndrome, must be considered.
Because the paramount challenge
of treating pregnant women with medi-
cations surrounds fetal and maternal
safety, ondansetron should be used
cautiously only after drugs with a betterDECEMBER 2014 Amsafety record, which have been labeled
to use in pregnancy (eg, doxylamine-
pyridoxine) have been tried.
The fetal safety of pyridoxine-
doxylamine
In contrast to ondansetron, the fetal safety
of the pyridoxine-doxylamine combina-
tion has been proven in numerous studies
and by several metaanalyses, making it
one of only few molecules receiving a
Pregnancy Category A classiﬁcation by
the FDA. Bendectin was the most
frequently prescribed antiemetic for the
treatment of nausea and vomiting be-
tween 1956 and 1983 with an estimated
33 million exposures. Originally, it was
formulated as a delayed-release combi-
nation of 10 mg doxylamine succinate,
10mg pyridoxine and 10mg dicyclomine
hydrochloride. However, in 1976, an
8-way study of doxylamine, pyridoxine
HCl, and dicyclomine showed that dicy-
clomine had no independent antiemetic
effect, and subsequently, bendectin was
reformulated excluding dicyclomine.14-16
To address the question of poten-
tial teratogenicity of the pyridoxine-
doxylamine combination in humans,
several metaanalyses were conducted,
which combined all controlled studies
of pregnancy outcome following the useerican Journal of Obstetrics& Gynecology 603
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ajog.org Obstetrics Clinical Opinionof this product during the ﬁrst trimester
of pregnancy. All of these analyses failed
to show an overall increase in malfor-
mation rates, or in speciﬁc malforma-
tions. A systematic review of 12 cohort
and 5 case-control studies totaling
200,000 patients, calculated an overall
summary OR of 1.01, with a 95% CI of
0.66e1.55. When the 2 types of studies
were separated according to their design,
the summary OR was 0.95 (95% CI,
0.62e1.45) for cohort studies, and 1.27
(95% CI, 0.83e1.94) for case-control
studies.17
A second metaanalysis synthesized
16 cohort and 11 case-control studies.
The relative risk for any malformation at
birth in association with exposure to
Bendectin in the ﬁrst trimester was 0.95
(95% CI, 0.88e1.04). Separate analyses
for cardiac defects, limb defects, oral
clefts and genital tract malformations
yielded pooled estimates of relative
risk ranging from 0.81 for oral clefts
to 1.11 for limb defects, with no differ-
ences in malformation rates between
the pyridoxine-doxylamine combina-
tion and the controls. As a group, these
studies have shown no differences in
the risk of birth defects between those
infants whose mothers had taken Bend-
ectin during the ﬁrst trimester of preg-
nancy and those who had not.18
An ecologic proof of the fetal safety
of the pyridoxine-doxylamine combina-
tion was published, showing that
the withdrawal of the drug from the
US market was not associated with
decreased rates of major congenital
malformations in general, or of any
speciﬁc malformation.19 In addition, the
pyridoxine-doxylamine combination is
one of very few drugs that have safety
information on the neurodevelopment of
children exposed in utero. A prospective
controlled cohort study of mother-child
pairs was conducted to determine the
effects of NVP and its treatment with the
pyridoxine-doxylamine combination on
child neurodevelopment. Three groups
of children were studied at 3-7 years of
age: 45 born to mothers who had NVP
and were exposed to the pyridoxine-
doxylamine combination, 47 with
mothers who had NVP but no pyridox-
ine- doxylamine was used, and 29 bornto mothers not experiencing NVP, and
mothers were assessed for IQ and socio-
economic status. The results showed
that the pyridoxine-doxylamine combi-
nation does not appear to adversely
affect fetal brain development and can
safely be used to treat NVP.20
In 1989, a report on the safety of
the pyridoxine/doxylamine combination
for use in the management of NVP was
prepared by a panel of Canadian and
American experts for the Special Advi-
sory Committee on Reproductive Phys-
iology to the Health Protection Branch
of Health Canada (currently called the
Health Products and Food Branch).
They concluded that “numerous studies
in animals and in humans that have
been reported in the scientiﬁc and
medical literature demonstrate that
Bendectin is not a teratogen.The safety
of the pyridoxine-doxylamine combi-
nation in the management of nausea and
vomiting of pregnancy has been estab-
lished by its use in many thousands
of pregnant women.”21 These conclu-
sions are similar to those leading the
FDA to approve this combination in
2013.2
Similarly, reputable teratogen refer-
ence guides concluded that the
pyridoxine-doxylamine combination is
not associated with an increased risk
for adverse pregnancy outcomes.22,23
Because of the extensive fetal safety data
that exist, the pyridoxine-doxylamine
combination received a FDA Pregnancy
Category A classiﬁcation, indicating that
adequate and well-controlled studies
have failed to demonstrate a risk to the
fetus in the ﬁrst trimester of pregnancy
and there is no evidence of risk in later
trimesters.2
The effectiveness of doxylamine-
pyridoxine
The clinical effectiveness of the delayed-
release combination of doxylamine and
pyridoxine has been documented over a
span of 50 years by several randomized,
controlled trials as well as in open post-
marketing studies. In addition, several
placebo-controlled clinical trials have
been published, the results of which
have conﬁrmed the effectiveness of this
combined agent (Table).DECEMBER 2014 AmCompelling evidence supporting the
effectiveness of this delayed-release com-
bination was provided by population-
based studies showing that the
withdrawal of the pyridoxine-doxylamine
combination from the US in 1983 was
temporally related to a 2- to 3-fold in-
crease in the rates of hospitalization of
women for NVP.3 These data suggest
that the doxylamine-pyridoxine combi-
nation is not only capable of eradicating
mild and moderate forms of NVP, but
also of preventing severe cases. Data
presented by Neutel reiterate these ﬁnd-
ings: during the 1990s the increased
use of the pyridoxine-doxylamine com-
bination by Canadian women has been
associated with a reduction in the hospi-
talization rates for severe NVP.
In conclusion, with the availability of
a safe and effective FDA-approved
drug for NVP, there is no reason for
women to be exposed to a drug of un-
proven maternal and fetal safety, which
has not been labeled for NVP. -
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